Restifo NP - Search Results

1

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ. Zeng R, et al. Among authors: restifo np. J Exp Med. 2005 Jan 3;201(1):139-48. doi: 10.1084/jem.20041057. J Exp Med. 2005. PMID: 15630141 Free PMC article.

2

A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.

Restifo NP, Spiess PJ, Karp SE, Mulé JJ, Rosenberg SA. Restifo NP, et al. J Exp Med. 1992 Jun 1;175(6):1423-31. doi: 10.1084/jem.175.6.1423. J Exp Med. 1992. PMID: 1588273 Free PMC article.

3

Identification of human cancers deficient in antigen processing.

Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, Bennink JR. Restifo NP, et al. J Exp Med. 1993 Feb 1;177(2):265-72. doi: 10.1084/jem.177.2.265. J Exp Med. 1993. PMID: 8426105 Free PMC article.

4

IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.

Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP. Rao JB, et al. Among authors: restifo np. J Immunol. 1996 May 1;156(9):3357-65. J Immunol. 1996. PMID: 8617961 Free PMC article.

5

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.

Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. Overwijk WW, et al. Among authors: restifo np. J Exp Med. 1998 Jul 20;188(2):277-86. doi: 10.1084/jem.188.2.277. J Exp Med. 1998. PMID: 9670040 Free PMC article.

6

Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.

Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Porgador A, et al. Among authors: restifo np. J Exp Med. 1998 Sep 21;188(6):1075-82. doi: 10.1084/jem.188.6.1075. J Exp Med. 1998. PMID: 9743526 Free PMC article.

7

Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.

Surman DR, Dudley ME, Overwijk WW, Restifo NP. Surman DR, et al. Among authors: restifo np. J Immunol. 2000 Jan 15;164(2):562-5. doi: 10.4049/jimmunol.164.2.562. J Immunol. 2000. PMID: 10623795 Free PMC article.

8

The future of interleukin-2: enhancing therapeutic anticancer vaccines.

Overwijk WW, Theoret MR, Restifo NP. Overwijk WW, et al. Among authors: restifo np. Cancer J Sci Am. 2000 Feb;6 Suppl 1(Suppl 1):S76-80. Cancer J Sci Am. 2000. PMID: 10685664 Free PMC article. Review.

9

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.

van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. van Elsas A, et al. Among authors: restifo np. J Exp Med. 2001 Aug 20;194(4):481-9. doi: 10.1084/jem.194.4.481. J Exp Med. 2001. PMID: 11514604 Free PMC article.

10

Assumptions of the tumor 'escape' hypothesis.

Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman DP, Theoret MR, Touloukian CE. Restifo NP, et al. Semin Cancer Biol. 2002 Feb;12(1):81-6. doi: 10.1006/scbi.2001.0399. Semin Cancer Biol. 2002. PMID: 11926416 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

356 results

Search Page

Filters